Loading…
← CockpitCompetitor Analysis › AUPH Aurinia Pharmaceuticals Inc.Open in the cockpit ↗

Aurinia Pharmaceuticals Inc.AUPHCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Markets Lupkynis, an oral therapy for lupus nephritis, a kidney complication of lupus.

Momentum weak 38
Mkt cap
$2.03B
US dollars, full cap
Free float
89%
of shares outstanding
$/day
$15.3M
20-day average traded
Fwd P/E
18.1×
forward earnings
ROIC−WACC
+37.7 pp
WACC 11.9%
Hurdle
-38 pp
Req g minus delivered
Next earnings
106 days
4 Mar 2027
Close · USD$15.13
1D-1.8%
1W-6.7%
1M-9.6%
3M-12.4%
6M-4.8%
YTD-5.1%
1Y-2.3%
ATR %3.3%
Beta0.65
52w lowhigh21.4% off high

What Aurinia Pharmaceuticals does

Markets Lupkynis, an oral therapy for lupus nephritis, a kidney complication of lupus.

Sells Lupkynis in the US itself, mainly through specialty pharmacies, so one product carries nearly all its revenue. Otsuka sells it in Europe and Japan and pays Aurinia royalties and supply revenue. It is prescribed alongside standard immune-suppressing treatment for lupus nephritis.

Products and services

  • Lupkynis (voclosporin, lupus nephritis)
  • Early pipeline

Customers

  • Nephrologists/rheumatologists

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Autoimmune kidney disease therapeutics

What could go right

  • Lupkynis revenue growth
  • International market expansion

What could go wrong

  • Competitive lupus nephritis entrants
  • Single-product revenue concentration

Moat: narrow (regulatory licence, IP / patents). First oral approved therapy for lupus nephritis with commercial exclusivity, though a niche market.

Headquarters: Edmonton, Canada · Founded: 1998 · Employees: 128

Named competitors

Aurinia Pharmaceuticals at a glance

Size Aurinia Pharmaceuticals (AUPH) is a United States Health Care company (Biotechnology) with a market value of $2.03B, the 1767th largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.13 on 18 Nov 2026.

Performance Over six months the shares fell 4.8%, against -10.8% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 21.0% over the last twelve months (peer median +0.3%); the operating margin is 44.8% (peer median -32.5%).

Valuation It trades at 18.1× forward earnings against a peer median of 58.3× (3rd cheapest of 5).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +41%, so the hurdle is -38 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 37.7 points above its cost of capital (11.9% WACC).

Short interest Short interest is 5.3% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026AUPH 98Peer median 92
Six months, rebased to 100: Aurinia Pharmaceuticals against the median of its 20 peers (local-currency closes).

Aurinia Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$322M$283M$235M$176M$134M
Revenue growth—+20%+34%+31%—
Gross profit$292M$250M$207M$161M$128M
EBITDA$163M$136M$33.5M-$71.7M-$110M
Net income$314M$287M$5.75M-$78.0M-$108M
Free cash flow$175M$135M$44.1M-$34.2M-$79.8M
Capital expenditure$132,110$252,000$281,000$718,000$292,000
Total debt$58.7M$74.8M$79.4M$97.6M$8.09M

Quarterly statements and history in the cockpit →

Aurinia Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%IMNMALMR300676TRVIMRVIPVLAZEAL688520REPLSEPNTRAXCOAG302440AUPH6-month return →1-month return →
Up and to the right = strong over both horizons. Aurinia Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×50×100×300676ZEALBCRX300601AUPHRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Aurinia Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%BCRX300601AUPHGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Aurinia Pharmaceuticals is the large dot.

Aurinia Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (AUPH vs NOVN.SW vs VERA vs GSK.L)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Aurinia Pharmaceuticals AUPH$2.03B-5%+21%45%18.1×3.5%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%
Vera Therapeutics VERA$1.85B-26%n/a-4,160%n/an/a
GSK GSK.L$97.9B-3%+4%25%10.4×-0.1%
Roche RO.SW$381B+21%-1%31%19.9×1.7%

How Aurinia Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Aurinia Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureAUPHPeer medianRank in peer set
1-month return-9.6%-1.6%6th lowest of 21
6-month return-4.8%-10.8%10th highest of 20
Distance from 52-week high-21.4%-34.1%5th highest of 21
Revenue growth (TTM)+21.0%+0.3%5th highest of 14
Operating margin44.8%-32.5%2nd highest of 13
Forward P/E18.1×58.3×3rd cheapest of 5
Growth the price implies (Req g, 7 yrs)3.5%n/a—
Growth delivered (Del g)+41.4%n/a—
Hurdle (Req g minus delivered)-37.9 ppn/a—
ROIC minus cost of capital+37.7 pp-12.2 pphighest of 8
EV / EBITDA9.8×n/a—
Net debt / EBITDA-2.6×1.1×2nd least indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%18.1×3.5%+41.4%
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/an/an/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%n/an/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%126.7×n/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%n/an/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%7.2×n/an/a
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%n/an/an/a
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%n/an/an/a
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%n/an/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%11.1×-11.0%+117.9%
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%n/an/an/a
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%105.5×22.7%+3.4%
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%n/an/an/a
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%n/an/an/a

Questions

Who are Aurinia Pharmaceuticals's main competitors?
Named competitors: Novartis (Fabhalta) (NOVN.SW), Vera Therapeutics (VERA), GSK (Benlysta) (GSK.L), Roche (RO.SW). The cockpit's measured peer set (industry) also includes Immunome (IMNM), Evopoint Biosciences (688837.SS), Alamar Biosciences (ALMR), BGI Genomics (300676.SZ), Trevi Therapeutics (TRVI), Maravai Lifesciences (MRVI).
Is Aurinia Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 18.1× against a peer median of 58.3×, 3rd cheapest of 5 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +41%, so the hurdle is -38 pp: the price already allows for a slowdown.
How has Aurinia Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -4.8% against -10.8% for the median peer; over one year -2.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.